Substance use disorders (SUDs) in oncology populations represent a significant yet underrecognized challenge, with prior research suggesting that up to 27 percent of cancer patients meet criteria for ...
This Journal feature begins with a case vignette highlighting a common clinical problem. Evidence supporting various strategies is then presented, followed by a review of formal guidelines, when they ...
The glucagon-like peptide 1 (GLP-1) receptor agonist semaglutide has made headlines as a US Food and Drug Administration (FDA)–approved treatment for type 2 diabetes (Ozempic) and obesity (Wegovy).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results